Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
11/22/2023
Locations: University of Washington, Seattle, Washington +1 locations
Conditions: Parkinson's Disease
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Recruiting
This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tas... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
11/21/2023
Locations: EverGreenHealth Neuroscience Institute, Kirkland, Washington
Conditions: Parkinson Disease, Tremor
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/20/2023
Locations: Evergreen Hospital Medical Center, Kirkland, Washington +1 locations
Conditions: Parkinson Disease
The GBA Multimodal Study in Parkinson's Disease
Recruiting
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessm... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/20/2023
Locations: University of Washington, Seattle, Washington
Conditions: Parkinson Disease, GBA Gene Mutation, Gaucher Disease
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Recruiting
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. F... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/17/2023
Locations: Neurology, Kirkland, Washington
Conditions: Parkinson Disease
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
Recruiting
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
Gender:
All
Ages:
All
Trial Updated:
11/14/2023
Locations: Swedish Neuroscience Institute, Seattle, Washington
Conditions: Parkinson Disease, Essential Tremor, Dystonia
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Evergreen Health, Kirkland, Washington +2 locations
Conditions: Parkinson's Disease
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Kirkland, Washington +1 locations
Conditions: Parkinson Disease
Use of CereGate Therapy for Freezing of Gait in PD
Recruiting
A Multi-Center, Controlled Study to Evaluate Use of CereGate Therapy to Reduce Freezing of Gait in Participants Diagnosed with Parkinson's Disease.
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
10/11/2023
Locations: University of Washington, Seattle, Washington
Conditions: Parkinson Disease, Freezing of Gait, Deep Brain Stimulation
Noninterventional Study Evaluating Parkinson's Disease Diary Use
Recruiting
This study aims to evaluate the impact of the frequency of assessments on the variability over time, reliability, and compliance for the Parkinson's disease (PD) diary in patients with PD in whom medications do not provide adequate control of symptoms.
Gender:
All
Ages:
Between 39 years and 70 years
Trial Updated:
09/12/2023
Locations: Evergreen Health Medical Center, Kirkland, Washington
Conditions: Parkinson's Disease
Rostock International Parkinson's Disease Study (ROPAD)
Recruiting
Rostock International Parkinson's Disease Study - An International, multicenter, epidemiological observational study aiming at identification of LRRK2-positive patients, the recruitment of 25,000 PD participants and the establishment of a candidate biomarker in the LRRK2-positive cohort.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
09/06/2023
Locations: Booth Gardner Parkinson's Care Center, Kirkland, Washington +1 locations
Conditions: Parkinson´s Disease
Flexible-Dose Trial in Early Parkinson's Disease (PD)
Recruiting
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
09/06/2023
Locations: Kirkland, Washington, Kirkland, Washington
Conditions: Parkinson Disease